Abstract
Refractory soft tissue sarcomas carry a poor prognosis and limited treatment options require the use of new chemotherapeutic agents. We report the case of an eight year old boy with non metastatic alveolar rhabdomyosarcoma of the right forearm (Group 3, Stage III). After treatment failure of several chemotherapeutic regimens and progression of his disease, Trabectedin was administered at 1.3 mg/m2/dose intravenously over 24 hours for two cycles. The patients quality of life improved as noted by a significant decrease in opiate requirements and ability to tolerate oral intake. The drug was well tolerated with the exception of transient neutropenia.
Keywords: ET-743, pediatric solid tumors, refractory sarcoma, Trabectedin, neutropenia, diagnosis, chemotherapeutic agents, palliative tumor, osteosarcoma, dose limiting toxicity
Current Drug Therapy
Title: Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma
Volume: 6 Issue: 2
Author(s): Roula A. Farah, Soumana C. Nasser, Racha A. Sabbagh, Pele B. Dina and Toufic A. Eid
Affiliation:
Keywords: ET-743, pediatric solid tumors, refractory sarcoma, Trabectedin, neutropenia, diagnosis, chemotherapeutic agents, palliative tumor, osteosarcoma, dose limiting toxicity
Abstract: Refractory soft tissue sarcomas carry a poor prognosis and limited treatment options require the use of new chemotherapeutic agents. We report the case of an eight year old boy with non metastatic alveolar rhabdomyosarcoma of the right forearm (Group 3, Stage III). After treatment failure of several chemotherapeutic regimens and progression of his disease, Trabectedin was administered at 1.3 mg/m2/dose intravenously over 24 hours for two cycles. The patients quality of life improved as noted by a significant decrease in opiate requirements and ability to tolerate oral intake. The drug was well tolerated with the exception of transient neutropenia.
Export Options
About this article
Cite this article as:
A. Farah Roula, C. Nasser Soumana, A. Sabbagh Racha, B. Dina Pele and A. Eid Toufic, Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma, Current Drug Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157488511795304912
DOI https://dx.doi.org/10.2174/157488511795304912 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview
Current Enzyme Inhibition Toxicity and Efficacy of Benzamide Riboside in Cancer Chemotherapy Models
Current Medicinal Chemistry Wnt Signaling in Development, Disease and Translational Medicine
Current Drug Targets Immunoglobulin G Expression and its Potential Role in Primary and Metastatic Breast Cancers
Current Molecular Medicine Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Harnessing the Tumor Suppressor Function of FOXO as an Alternative Therapeutic Approach in Cancer
Current Drug Targets p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design GLUT4 Goes Abnormal: Disregulation of the Insulin-Responsive Glucose Transporter in Abnormal Metabolic States
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents NBS1 Heterozygosity and Cancer Risk
Current Genomics Role and Treatment of Mitochondrial DNA-Related Mitochondrial Dysfunction in Sporadic Neurodegenerative Diseases
Current Pharmaceutical Design Crocins: The Active Constituents of Crocus Sativus L. Stigmas, Exert Significant Cytotoxicity on Tumor Cells In Vitro
Current Cancer Therapy Reviews Zebrafish Model in Drug Safety Assessment
Current Pharmaceutical Design Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence
Current Pharmaceutical Design The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Computed Tomography (CT) Features of Pelvic Rhabdomyosarcoma (RMS) in Children
Current Medical Imaging Anti-Apoptotic Actions of Insulin-Like Growth Factors: Lessons from Development and Implications in Neoplastic Cell Transformation
Current Pharmaceutical Design